Anavex Life Sciences
AVXL · Nasdaq · United States
Share price · AVXL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AVXL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-9.5%
Nothing announced by AVXL that day or the session before.
- 16 Nov 2026-12.4%
Nothing announced by AVXL that day or the session before.
- 5 Oct 2026-9.6%
- 30 Sep 2026-14.4%
Nothing announced by AVXL that day or the session before.
- 26 Aug 2026-9.0%
- 25 Aug 2026+14.5%
- 3 Aug 2026+7.3%
- 25 Mar 2026-34.6%
- 23 Mar 2026+9.4%
- 3 Dec 2025+24.5%
Nothing announced by AVXL that day or the session before.
Share of unusual movement by asset
For each asset, the share of AVXL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | Sigma-1 receptor / muscarinic receptor (dual)Small molecule | Alzheimer's Disease | |
| Phase 2 | Sigma-1 receptor / muscarinic receptor (dual)Small molecule | Schizophrenia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | — | $118M | —-$9.1M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $4.2M | $127M | $5.3M-$4.4M operating cash flow | report ↗ |
| 2025-Q4 | — | $4.7M | $132M | $5.7M-$7.2M operating cash flow | report ↗ |
| 2025-Q2 | — | $10.0M | $101M | $13M-$12M operating cash flow | report ↗ |
| 2025-Q1 | — | $9.9M | $116M | $11M-$5.9M operating cash flow | report ↗ |
| 2024-Q4 | — | $10M | $121M | $12M-$12M operating cash flow | report ↗ |
| 2024-Q2 | — | $12M | $139M | $12M-$5.2M operating cash flow | report ↗ |
| 2024-Q1 | — | $9.7M | $139M | $11M-$12M operating cash flow | report ↗ |
| 2023-Q4 | — | $8.7M | $144M | $8.6M-$7.3M operating cash flow | report ↗ |
| 2023-Q2 | — | $10M | $155M | $11M-$7.7M operating cash flow | report ↗ |
| 2023-Q1 | — | $11M | $153M | $13M-$8.5M operating cash flow | report ↗ |
| 2022-Q4 | — | $12M | $144M | $13M-$5.8M operating cash flow | report ↗ |
| 2022-Q2 | — | $9.3M | $153M | $12M-$7.0M operating cash flow | report ↗ |
| 2022-Q1 | — | $8.6M | $153M | $10M-$9.6M operating cash flow | report ↗ |
| 2021-Q4 | — | $8.7M | $151M | $11M-$3.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $38M | $103M | $12M-$39M operating cash flow | report ↗ |
Anavex Life Sciences reported fiscal 2025 results with revenue not disclosed, R&D spend of $37.59M, down 10.2% YoY, and cash and cash equivalents of $102.58M. The company posted a net loss of $46.38M for the year.
Management guided to an approximate cash runway of more than 3 years at the current cash utilization rate. Blarcamesine received a negative trend vote from the CHMP on its European Marketing Authorisation Application, and the company intends to request a re-examination. ANAVEX3-71 met its primary safety endpoint in a placebo-controlled Phase 2 schizophrenia study, with encouraging trends in secondary and exploratory analyses. The company also highlighted upcoming regulatory and clinical trial updates across its pipeline, including early Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and a Phase 2/3 design for Fragile X, along with recent peer-reviewed publications and planned conference presentations.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-03 | Paeger Axel · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2026-11-03 | Kellmeyer Terrie · director, President and CEO | Award / grant (derivative) | 200,000 | — | — | Form 4 |
| 2026-11-03 | Donhauser Peter D.O. · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2026-11-03 | Velden Claus Vander · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2026-09-24 | Boenisch Sandra · PFO & Treasurer | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2026-09-24 | Boenisch Sandra · PFO & Treasurer | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-09-24 | Boenisch Sandra · PFO & Treasurer | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-09-24 | Boenisch Sandra · PFO & Treasurer | Award / grant (derivative) | 25,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 188 reporting institutions held 39.6M shares ($118.8M, 42.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 7,609,618 | $23.4M |
| 2 | STATE STREET CORP | 4,512,028 | $13.9M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 3,863,950 | $11.9M |
| 4 | TWO SIGMA INVESTMENTS, LP | 3,247,888 | $10.0M |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2,188,275 | $6.7M |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 995,663 | $3.1M |
| 7 | Summit Financial, LLC | 940,455 | $2.9M |
| 8 | BANK OF AMERICA CORP /DE/ | 863,150 | $2.6M |
| 9 | GOLDMAN SACHS GROUP INC | 804,435 | $2.5M |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 783,148 | $2.4M |
| 11 | AQR CAPITAL MANAGEMENT LLC | 756,792 | $2.3M |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 756,558 | $2.3M |
| 13 | NORTHERN TRUST CORP | 725,187 | $2.2M |
| 14 | JANE STREET GROUP, LLC | 725,003 | $2.2M |
| 15 | VANGUARD FIDUCIARY TRUST CO | 647,169 | $2.0M |